These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 29140271)

  • 1. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.
    Yamaoka T; Ohba M; Ohmori T
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29140271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
    Zhou J; Ji Q; Li Q
    J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quest to overcome resistance to EGFR-targeted therapies in cancer.
    Chong CR; Jänne PA
    Nat Med; 2013 Nov; 19(11):1389-400. PubMed ID: 24202392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].
    Ni L; Nie L
    Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
    Dhomen NS; Mariadason J; Tebbutt N; Scott AM
    Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Third Shot at EGFR: New Opportunities in Cancer Therapy.
    Guardiola S; Varese M; Sánchez-Navarro M; Giralt E
    Trends Pharmacol Sci; 2019 Dec; 40(12):941-955. PubMed ID: 31706618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer.
    Zhou Y; Takahashi JI; Sakurai H
    Biol Pharm Bull; 2024; 47(5):895-903. PubMed ID: 38692865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
    Wykosky J; Fenton T; Furnari F; Cavenee WK
    Chin J Cancer; 2011 Jan; 30(1):5-12. PubMed ID: 21192840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.
    Yu HA; Riely GJ; Lovly CM
    Clin Cancer Res; 2014 Dec; 20(23):5898-907. PubMed ID: 25303979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer].
    Zhang H; Zhang S
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):61-65. PubMed ID: 28103975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
    Efferth T
    Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
    Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
    Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
    Ayati A; Moghimi S; Salarinejad S; Safavi M; Pouramiri B; Foroumadi A
    Bioorg Chem; 2020 Jun; 99():103811. PubMed ID: 32278207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.